Vanda is criticizing the FDA’s restrictions on information companies can provide regarding off-label use of approved ...

The Washington Capitals announced today ALL CAPS 2025 Playoffs initiatives presented by Vanda Pharmaceuticals Inc.

After years of back-and-forth with the FDA over Hetlioz's potential use as a jet lag disorder treatment, Vanda ...

Future Pak—whose acquisition offer was rejected by Vanda Pharmaceuticals last summer—is offering to buy Theratechnologies for ...

Vanda's strong financials and product lineup show promise, but management concerns and FDA disputes may hinder growth. Learn ...

The HIV-focused biopharma has received its latest bid from CDMO Future Pak for a cool $255 million, but the drugmaker had to ...

VNDA opened at $4.50 on Tuesday. Vanda Pharmaceuticals has a 12-month low of $3.87 and a 12-month high of $6.75. The firm has a market capitalization of $262.42 million, a P/E ratio of -14.06 and ...

Vanda Pharmaceuticals (VNDA) announced that a New Drug Application was submitted to the U.S. FDA requesting marketing approval of Bysanti for ...

WASHINGTON, March 31, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that a New Drug Application (NDA) was submitted to the U.S. Food and Drug ...

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today ...

Highlights,Vanda Pharmaceuticals posts improved earnings, surpassing market expectations.,Company executives increase stock positions, reflecting confidence in future growth.,Strong institutional ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...